Brian Buntz is a Pharma Editor with a focus on the pharmaceutical industry. He writes for publications such as Drug Discovery & Development and Medical Design Sourcing, covering topics ranging from medication promotion to future-readiness rankings in the pharma sector. His work has also been featured in Medical Design & Outsourcing, TED Conferences, and MassDevice.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Brian Buntz's articles primarily focus on the healthcare and pharmaceutical industry, with a strong emphasis on data-driven insights. His coverage suggests an interest in topics such as pharmaceutical innovation, M&A activity, emerging trends in drug approvals, and AI applications within healthcare.
Given his reliance on citing data and press releases, Brian may be interested in pitches that provide comprehensive data analysis or newsworthy findings related to pharmaceuticals, medical research advancements, or trends in healthcare technology. Additionally, he might be open to receiving press releases announcing significant developments within the healthcare and pharmaceutical sectors.
While Brian's geographic focus is not specified, his coverage appears to encompass global perspectives on the healthcare and pharmaceutical industry. Therefore, relevant pitches should consider international implications or broader industry trends rather than focusing solely on specific regional matters unless they have global significance.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Brian Buntz
| The FDA has signed off on two novel therapies targeting rare pediatric cancers.
By: Brian Buntz
| The recent emergence of H5N1 avian influenza in humans and animals has intensified global efforts to prepare for a potential pandemic.
By: Brian Buntz
While it is easy for individuals to dabble with the technology, quantifying the actual enterprise value for biopharma firms is often less clear. “We
By: Brian Buntz
| As machine learning and deep learning technologies advance thanks to advances in computation, algorithms and data availability, the possibilities of the technology continue to expand in medicine.
By: Brian Buntz
| Cell and gene therapies are upending the treatment of a growing number of diseases by addressing the underlying causes of genetic disorders.
By: Brian Buntz
| The same week that BenevolentAI announced it was cutting 30% of its staff, AI-focused biotech Xaira debuted with a $1 billion funding round with little precedent in healthcare over the past year.
By: Brian Buntz
In this age of rapidly evolving technologies that fundamentally shift the way businesses operate, such as large language models (LLMs) and natural
By: Brian Buntz
| In the rapidly evolving landscape of drug development, real-world evidence (RWE) is making significant strides, finding its way into the early stages of the process.
By: Brian Buntz
| Friso Postma, vice president of AI for drug discovery at BioXcel Therapeutics , prefers the term “augmented intelligence” to “artificial
By: Brian Buntz
| On March 6, 2024, the U.S. Securities and Exchange Commission approved a rule to require some companies to report some of their carbon emissions (Scope 1 and 2, but not Scope 3)
(833) 317-6278 
